These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17567623)

  • 1. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study.
    Chiodini BD; Franzosi MG; Barlera S; Signorini S; Lewis CM; D'Orazio A; Mocarelli P; Nicolis E; Marchioli R; Tognoni G; ;
    Eur Heart J; 2007 Aug; 28(16):1977-83. PubMed ID: 17567623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of genetic variants associated with response to statin therapy.
    Mega JL; Morrow DA; Brown A; Cannon CP; Sabatine MS
    Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1310-5. PubMed ID: 19667110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype.
    Ilveskoski E; Lehtimäki T; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Laippala P; Karhunen PJ; Knuuti J
    Scand J Clin Lab Invest; 2007; 67(7):723-34. PubMed ID: 17852827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
    Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction.
    Nakaya R; Uzui H; Shimizu H; Nakano A; Mitsuke Y; Yamazaki T; Ueda T; Lee JD
    Int J Cardiol; 2005 Oct; 105(1):67-73. PubMed ID: 16207547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
    Donnelly LA; Palmer CN; Whitley AL; Lang CC; Doney AS; Morris AD; Donnan PT
    Pharmacogenet Genomics; 2008 Apr; 18(4):279-87. PubMed ID: 18334912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
    Boekholdt SM; Agema WR; Peters RJ; Zwinderman AH; van der Wall EE; Reitsma PH; Kastelein JJ; Jukema JW;
    Circulation; 2003 May; 107(19):2416-21. PubMed ID: 12742999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients.
    Kobashigawa JA; Moriguchi JD; Laks H; Wener L; Hage A; Hamilton MA; Cogert G; Marquez A; Vassilakis ME; Patel J; Yeatman L
    J Heart Lung Transplant; 2005 Nov; 24(11):1736-40. PubMed ID: 16297773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.
    Sabatine MS; Ploughman L; Simonsen KL; Iakoubova OA; Kirchgessner TG; Ranade K; Tsuchihashi Z; Zerba KE; Long DU; Tong CH; Packard CJ; Pfeffer MA; Devlin JJ; Shepherd J; Campos H; Sacks FM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):562-7. PubMed ID: 18174457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
    Thompson PL; Meredith I; Amerena J; Campbell TJ; Sloman JG; Harris PJ;
    Am Heart J; 2004 Jul; 148(1):e2. PubMed ID: 15215811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased mortality associated with statin treatment in patients with acute myocardial infarction and lymphotoxin-alpha C804A polymorphism.
    Suna S; Sakata Y; Nakatani D; Okuda K; Shimizu M; Usami M; Matsumoto S; Hara M; Ozaki K; Mizuno H; Minamino T; Takashima S; Nishino M; Matsumura Y; Takeda H; Tanaka T; Sato H; Hori M; Komuro I
    Atherosclerosis; 2013 Apr; 227(2):373-9. PubMed ID: 23398946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients.
    Vaisi-Raygani A; Rahimi Z; Nomani H; Tavilani H; Pourmotabbed T
    Clin Biochem; 2007 Oct; 40(15):1150-6. PubMed ID: 17689519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of plasma high sensitive C-reactive protein in detecting three-vessel coronary artery disease: modification by apolipoprotein E genotype.
    Mennander A; Kuukasjärvi P; Laurikka J; Nikus K; Karhunen PJ; Tarkka M; Lehtimäki T
    Scand J Clin Lab Invest; 2008; 68(8):714-9. PubMed ID: 18609102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
    Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
    Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
    Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
    Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction?
    Lorenz H; Jünger C; Seidl K; Gitt A; Schneider S; Schiele R; Wienbergen H; Winkler R; Gottwik M; Delius W; Senges J; Rauch B
    Eur Heart J; 2005 Jun; 26(11):1078-85. PubMed ID: 15728647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E polymorphism and central nervous system tumors: correlation with cell proliferation indices and clinical outcome.
    Zunarelli E; Nicoll JA; Trentini GP
    Clin Neuropathol; 2000; 19(1):1-6. PubMed ID: 10774944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust association of the APOE epsilon4 allele with premature myocardial infarction especially in patients without hypercholesterolaemia: the Aachen study.
    Schmitz F; Mevissen V; Krantz C; Kimmel M; Erdmann J; Hoffmann R; Zerres K; Ortlepp JR
    Eur J Clin Invest; 2007 Feb; 37(2):106-8. PubMed ID: 17217375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.